Results 1 to 10 of about 50,674 (166)
Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]
Diversifying the sp 3 -rich triquinazine core, we prepared four new chiral scaffolds and 26 analogues that reveal how subtle structural changes modulate Janus Kinase activity, yielding a potent JAK1 inhibitor comparable to FDA-approved drugs.
Mulliri K +5 more
europepmc +3 more sources
Janus kinase inhibitor audit [PDF]
Beck J, Banford S.
europepmc +2 more sources
Janus Kinase Inhibitors and Cell Therapy [PDF]
Cellular therapies such as allogeneic hematopoietic stem cell transplantation (HSCT) and immune-effector cell therapy (IECT) continue to have a critical role in the treatment of patients with high risk malignancies and hematologic conditions. These therapies are also associated with inflammatory conditions such as graft-versus-host disease (GVHD) and ...
Amer Assal +2 more
openaire +3 more sources
Itch and Janus Kinase Inhibitors
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a
Yujin Han +4 more
openaire +3 more sources
Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj +1 more source
Role of Janus Kinase Inhibitors in Therapy of Psoriasis [PDF]
Janus kinases inhibitors are molecules that target Janus kinases—signal transducers and activators of transcription (JAK/STAT). They inhibit this intracellular signal pathway, blocking the gene transcription of crucial proinflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases, including ...
Sylwia Słuczanowska-Głąbowska +3 more
openaire +2 more sources
The use of Tofacitinib in the treatment of inflammatory bowel disease [PDF]
Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus ...
E L Nasonov +2 more
doaj +1 more source
Peripheral neuropathy associated with tofacitinib use in alopecia universalis
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Alopecia universalis (AU) is the advanced form of AA characterized by complete scalp and body hair loss.
Raghad Alharthi +4 more
doaj +1 more source
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz +6 more
doaj +1 more source
Glucocorticoids combined with tofacitinib for systemic sarcoidosis with rash as initial symptom: a case report [PDF]
Systemic sarcoidosis is a granulomatous disease involving multiple organs and systems. A 36-year-old woman was admitted due to multiple nodules of the trunk for 4 months. Upon admission, laboratory and auxiliary examinations were performed.
Hu Rongrong, Hong Yixin, Su Xiangyang, Ma Guiyan, Chen Peiran
doaj +1 more source

